HIGHBuilt-in & outside partyProduct / Revenue mix
Omnipod product platform
“10-K Item 1A: 'We expect to continue to derive nearly all our revenue from our Omnipod product platform'”
PODD · Concentration risk · 10-K extracted
Insulet (PODD) concentration risks
Updated
The most significant concentration Insulet discloses is Omnipod product platform, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Insulet’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 7 disclosed concentrations
HIGH3
MEDIUM4
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
sole-sourced components
“10-K Item 1: 'we are sole-sourced, with the supplier controlling the intellectual property rights'”
HIGHOutside partyCustomer
Amgen (Drug Delivery)
“10-K Item 1A: 'Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen's Neulasta Onpro kit'”
MEDIUMBuilt-inGeographic
28%
International
“10-K Item 1A: 'International sales made up 28% of our revenues in 2025'”
MEDIUMOutside partyCustomer
27%
Distributor A
“10-K Item 1: 'Distributor A| 27%'”
MEDIUMOutside partyCustomer
26%
Distributor B
“10-K Item 1: 'Distributor B| 26%'”
MEDIUMOutside partyCustomer
25%
Distributor C
“10-K Item 1: 'Distributor C| 25%'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is among the most layered in the disclosed peer set, combining high-share product, supplier, and customer dependencies with medium-share geographic and distributor exposures. The foundational risk is product: the company expects to continue deriving nearly all revenue from the Omnipod product platform — a high-share, mixed-character concentration that is both the deliberate strategic focus and a binary dependency on a single product's clinical and commercial success. Alongside this, sole-sourced components with supplier-controlled intellectual property create a high-share supply dependency: disruption at a sole-source supplier cannot be quickly remedied given the IP and qualification barriers to switching. The Drug Delivery business adds a high-share counterparty dependency: substantially all commercialized Drug Delivery revenue consists of sales of a customized version of the product for Amgen's Neulasta Onpro kit. This is a single-program, single-customer exposure within a distinct revenue line; any change in Amgen's commercial strategy for that kit would directly eliminate that revenue stream. On the distribution side, three distributors each account for medium shares of revenue: Distributor A at 27%, Distributor B at 26%, and Distributor C at 25%. Together these three relationships account for a very large share of the commercial channel; a disruption to any one would be visible in reported results. International sales made up 28% of revenues in 2025 — a medium-share geographic exposure with currency and market-access implications. The concentration profile is dense across multiple dimensions and is the most important risk feature of the investment case.
For the engine’s reasoning on PODD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| PODD● | Insulet Corporation | 3 | 4 | 0 | 7 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.